secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001104659-24-003903
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist details rusfertide Ph3 enrollment, JNJ-2113 milestones, cash runway through Q1 2026
--------------------------------------------------------------------------------

- Rusfertide VERIFY Ph3 enrollment expected to complete 1Q24; NDA filing planned for Q4 2024.
- JNJ-2113 ICONIC Ph3 program ongoing; ANTHEM UC Ph2b expected completion ~May 2025.
- Oral IL-17 peptide antagonist development candidate on track for 2024.
- Cash runway forecast through Q1 2026; $215M potential milestones from Janssen not included.
- $172.5M in upfront and development milestones achieved, including $60M in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924003903/0001104659-24-003903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924003903/tm243318d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-003903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer